$59.75+15.50% · 3M
Moving avg
1W-0.40%
1M-7.08%
3M+15.50%
6M+42.47%
YTD+34.30%
1Y+54.63%
3Y+52.00%
5Y+237.76%
52-week range
$35.6065% of range$72.66
Company health
Value0/6
Growth0/6
Profitability1/6
Health5/6
Dividend0/6
Bull vs bear
Strengths
- Analysts see 45% upside to a $87 target
- Analyst consensus is "Buy"
- Net cash on the balance sheet
Risks
- Currently unprofitable
- Burning free cash flow
- Revenue shrinking 15% a year
Key statistics
Valuation
Market cap
$5.78B
Enterprise value
$5.73B
P/E ratio (TTM)
-12.75x
P/S ratio (TTM)
0.00x
EV/EBITDA
-13.74x
Per share & returns
EPS (TTM)
-$4.11
Dividend yield
0.00%
Beta (1Y)
0.63
30-day change
-7.08%
Trading
Volume (24h)
459.13K
Previous close
$60.40
Shares outstanding
96.67M
About Xenon Pharmaceuticals Inc.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Symbol
XENE
Xenon Pharmaceuticals Inc. is a mid-cap healthcare company in the Biotechnology industry.
Frequently asked questions
What is Xenon Pharmaceuticals Inc.'s market cap?
Xenon Pharmaceuticals Inc. (XENE) has a market capitalization of $5.78B.
What sector is Xenon Pharmaceuticals Inc. in?
Xenon Pharmaceuticals Inc. operates in the Healthcare sector, Biotechnology industry.
What exchange does XENE trade on?
XENE trades on NASDAQ.
Appears in
Eli Lilly and CompanyLLY
$1,148.20-0.98%
$1.08T cap
Johnson & JohnsonJNJ
$275.23-1.15%
$663.28B cap
AbbVie Inc.ABBV
$256.34-1.49%
$452.90B cap
Merck & Co., Inc.MRK
$150.34-1.31%
$371.31B cap
UnitedHealth Group IncorporatedUNH
$397.14-0.95%
$360.66B cap
Roche Holding AGSWX: ROP
CHF 357.00+0.14%
$350.91B cap
Novartis AGSWX: NOVN
CHF 129.58-1.33%
$304.13B cap
AstraZeneca PLCLON: AZN
£120.06-1.15%
$251.66B cap